Full video transcriptClick to expand
Auto-generated transcript of @courtneyannklang's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I lost 98 pounds on a GLP1 and I'm currently in my maintenance stage.
- 0:04So here's a little breakdown of what exactly that looks like for me.
- 0:08And I started my journey.
- 0:09I got all the way up to 10 milligrams and then I worked my way down to 7.5.
- 0:15I did one week at five milligrams and then my anxiety got the rest of me and I
- 0:21gained five pounds, but it was also the week of my period, but that freaked me out.
- 0:24So I went back up to 7.5 and I just did my dose this morning.
- 0:29And I am going to be going down 0.5 every week.
- 0:32I was deciding if I wanted to do 7.5 and just try to go two weeks or if I wanted to
- 0:39go from 7.5 to five maintenance looks different for each person because each
- 0:43person's journey is different.
- 0:45So I decided that what I'm going to do for myself, for my maintenance journey is
- 0:50I'm going to titrate down 0.5 every week.
- 0:53So I did 7.5 last week.
- 0:55I just did 7 today and next week I will do the 6.5 and so on until I get down to 2.5.
- 1:02And then once I met 2.5, we'll see how long I go with that before I decide if I
- 1:07want to get off completely or I've also seen some people just do 2.5 once a month.
- 1:12I feel like everybody's journey is different, but that is what I will be doing
- 1:16as far as maintenance down on my GLP one.
- 1:20And if I ever decide to get off of it, you guys will be the first to know.
GLP-1 maintenance plans: what the science says about staying off
Quick answer
The creator is self-managing a tirzepatide taper from 7.5mg to a target of 2.5mg using 0.5mg weekly reductions, with no clinical protocol cited. This approach is not validated in published literature, and tirzepatide's five-day half-life raises questions about the pharmacological rationale for monthly 2.5mg dosing as a maintenance strategy. Weight regain following GLP-1 discontinuation is well-documented and driven by the return of baseline appetite-regulating physiology, not willpower deficits.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 maintenance plans: what the science says about staying off, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 maintenance plans: what the science says about staying off is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 maintenance plans: what the science says about staying off" from Courtney Klang. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-managing a tirzepatide taper from 7.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to kassiroll here s my maintenance plan and what ha." In this clip, the useful excerpt is: "I lost 98 pounds on a GLP1 and I'm currently in my maintenance stage." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is self-managing a tirzepatide taper from 7.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is self-managing a tirzepatide taper from 7.5mg to a target of 2.5mg using 0.5mg weekly reductions, with no clinical protocol cited. This approach is not validated in published literature, and tirzepatide's five-day half-life raises questions about the pharmacological rationale for monthly 2.5mg dosing as a maintenance strategy. Weight regain following GLP-1 discontinuation is well-documented and driven by the return of baseline appetite-regulating physiology, not willpower deficits.
- Tirzepatide has a half-life of roughly 5 days, which means monthly 2.5mg dosing would likely produce no meaningful sustained pharmacological effect.
- The STEP 1 extension trial (Wilding et al., 2022, NEJM) found that patients who stopped semaglutide regained about two-thirds of lost weight within 12 months, underscoring how dose-dependent these medications are.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Tirzepatide has a half-life of roughly 5 days, which means monthly 2.5mg dosing would likely produce no meaningful sustained pharmacological effect.
- The STEP 1 extension trial (Wilding et al., 2022, NEJM) found that patients who stopped semaglutide regained about two-thirds of lost weight within 12 months, underscoring how dose-dependent these medications are.
- Normal menstrual cycle fluid retention of 1-5 pounds is well-documented by ACOG and should not be interpreted as medication-driven weight regain during a taper.
- No published randomized trial validates a specific weekly taper schedule for GLP-1 medications in a weight maintenance context. This is an improvised approach, not a clinical standard.
- Rubino et al. (2023, Obesity) found that behavioral factors, including dietary habits and physical activity, influenced how much weight participants regained after stopping GLP-1 therapy.
- Any tapering plan for a GLP-1 medication should involve a prescribing clinician who can monitor metabolic markers, not just the scale reading.
- The creator's framing of this as her personal plan rather than universal advice is more responsible than typical GLP-1 content, but platform reach means the distinction gets lost for many viewers.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @courtneyannklang actually say?
Courtneyann says she lost 98 pounds on a GLP-1, peaked at 10mg, and is now tapering down by 0.5mg each week from 7.5mg, with a goal of reaching 2.5mg. She mentioned a brief dip to 5mg triggered a 5-pound regain she attributed to anxiety and her menstrual cycle. Her plan is to eventually try 2.5mg monthly as a possible long-term floor.
To be clear: she is sharing her personal protocol, not prescribing one. But with 17,900 views, personal anecdote functions like advice whether intended or not. That matters when the topic is a drug class with well-documented rebound weight gain data behind it.
Does the science back this up?
Partially, but the optimism here deserves some friction. The concept of tapering GLP-1 doses to find a minimum effective maintenance dose is clinically reasonable, but the evidence for what that looks like in practice is thin.
The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) showed that participants who stopped semaglutide regained roughly two-thirds of their lost weight within one year. That study involved full discontinuation, not a taper, but it established the central problem: GLP-1 medications appear to work while you take them and stop working when you don't. A slower taper does not change the underlying biology, which involves appetite-regulating pathways that return to baseline once the drug is removed.
There is no published randomized trial testing a 0.5mg-per-week tapering schedule for tirzepatide or semaglutide in maintenance. This protocol appears to be clinician-improvised or community-derived, not evidence-based in a formal sense. That does not make it wrong. It makes it untested.
What did they get wrong (or right)?
She gets credit for saying "maintenance looks different for each person" and framing this as her personal plan rather than a universal prescription. That kind of hedging is more responsible than most GLP-1 content on TikTok.
What's shakier is the framing that a rapid drop to 5mg was destabilizing and caused a 5-pound gain. Weight fluctuation of 5 pounds over a week, especially around menstruation, is almost certainly water retention, not fat regain. The American College of Obstetricians and Gynecologists has documented luteal-phase fluid retention of 1-5 pounds as normal. Attributing this to dose reduction and responding by increasing the dose again raises a concern: if every normal weight fluctuation triggers a dose increase, tapering may never actually happen.
The 2.5mg once-monthly idea at the end of the video is the part that needs the most scrutiny. There is no pharmacokinetic data supporting monthly dosing as maintaining meaningful GLP-1 receptor agonism. Tirzepatide has a half-life of approximately five days (Frias et al., 2021, New England Journal of Medicine), meaning a monthly 2.5mg dose would likely produce negligible sustained effect.
What should you actually know?
GLP-1 medications are not designed with a formal off-ramp. Most clinical guidelines currently treat them as chronic medications for chronic conditions, similar to antihypertensives. The idea of tapering to zero is appealing, but the biology doesn't particularly support it without lifestyle infrastructure to compensate.
That does not mean tapering is wrong. Some patients do maintain weight loss after discontinuation, particularly those who have made durable changes to eating behavior and physical activity. A 2023 analysis in Obesity (Rubino et al.) found that behavioral factors moderated post-discontinuation regain, though most participants still regained significant weight.
What Courtneyann is describing is a reasonable, individualized experiment. What it is not is a validated protocol. Anyone considering a similar approach should do it with clinical supervision, not based on a TikTok taper schedule, because the variables that determine whether you maintain weight loss are highly individual and worth tracking with a provider, not just a ring light.
- Half-life of tirzepatide is roughly 5 days, which affects how meaningful any given dose interval actually is.
- Menstrual cycle weight fluctuations are normal and should not be interpreted as medication failure.
- Stopping GLP-1 therapy without behavioral scaffolding is associated with significant weight regain in most published studies.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Courtney Klang · TikTok creator
17.9K views on this video
Replying to @Kassiroll here’s my maintenance plan and what happens next!! #glp1 #glp1forweightloss #foryoupage #fyp #viral
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide has a half-life of roughly 5 days,?
Tirzepatide has a half-life of roughly 5 days, which means monthly 2.5mg dosing would likely produce no meaningful sustained pharmacological effect.
What does the video say about the step 1 extension trial (wilding et al., 2022, nejm)?
The STEP 1 extension trial (Wilding et al., 2022, NEJM) found that patients who stopped semaglutide regained about two-thirds of lost weight within 12 months, underscoring how dose-dependent these medications are.
What does the video say about normal menstrual cycle fluid retention of 1-5 pounds?
Normal menstrual cycle fluid retention of 1-5 pounds is well-documented by ACOG and should not be interpreted as medication-driven weight regain during a taper.
What does the video say about no published randomized trial validates a specific weekly taper schedule?
No published randomized trial validates a specific weekly taper schedule for GLP-1 medications in a weight maintenance context. This is an improvised approach, not a clinical standard.
What does the video say about rubino et al. (2023, obesity) found?
Rubino et al. (2023, Obesity) found that behavioral factors, including dietary habits and physical activity, influenced how much weight participants regained after stopping GLP-1 therapy.
What does the video say about any tapering plan for a glp-1 medication should involve a?
Any tapering plan for a GLP-1 medication should involve a prescribing clinician who can monitor metabolic markers, not just the scale reading.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Courtney Klang, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.